Industry News
Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced melanoma
Sep 30, 2014
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with... Read More
Melanoma drug combo improves patient survival rate, decreases risk of harsh side effect
Sep 30, 2014
A UCLA researcher at the Jonsson Comprehensive Cancer Center helped pioneer a new therapy that combines the drug Zelboraf® with an experimental drug cobimetinib, allowing metastatic melanoma... Read More
AZD9291 shows durable clinical response in patients with advanced EGFR mutation positive non-small cell lung cancer
Sep 30, 2014
Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8. Read More
Promising results shown with targeted approaches in subsets of non-small cell lung cancer
Sep 30, 2014
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according... Read More
Studies report new findings on treatment options for mesothelioma
Sep 30, 2014
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to... Read More
IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
Sep 30, 2014
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in... Read More
Adding cediranib to chemotherapy improves progression-free survival for metastatic or recurrent cervical cancer, phase II trial shows
Sep 30, 2014
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage... Read More
Significant presence of women in oncology, but still under-representation in leadership positions, Greek survey shows
Sep 30, 2014
A growing number of oncologists in Greece are female, but women continue to be under-represented in leadership positions, according to a survey reported at the ESMO 2014 Congress. Read More
Many patients lack information about the use of targeted therapies, oncologists say
Sep 30, 2014
More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey... Read More
Docs toolkits to tackle treatment of blood poisoning, UK
Sep 30, 2014
A Good Hope Hospital consultant is changing the way treatment of blood poisoning is managed by health care professionals with a suite of new toolkits. Read More
Previous Page Next Page